Abstract:Background: Studies have shown that the natural products of Astragalus membranaceus (AM) can effectively interfere with a variety of cancers, but their mechanism of action on breast cancer remains unclear. Triple-negative breast cancer (TNBC) is associated with a severely poor prognosis due to its invasive phenotype and lack of biomarker-driven-targeted therapies. In this study, the potential mechanism of the target composition acting on TNBC was explored by integrated pharmacological models and in vitro experiments.Materials and Methods: Based on the Gene Expression Omnibus (GEO) database and the relational database of Traditional Chinese Medicines (TCMs), the drug and target components were initially screened to construct a common network module, and multiattribute analysis was then used to characterize the network and obtain key drug-target information. Furthermore, network topology analysis was used to characterize the betweenness and closeness of key hubs in the network. Molecular docking was used to evaluate the affinity between compounds and targets and obtain accurate combination models. Finally, in vitro experiments verified the key component targets. The cell counting kit-8 (CCK-8) assay, invasion assay, and flow cytometric analysis were used to assess cell viability, invasiveness, and apoptosis, respectively, after Astragalus polysaccharides (APS) intervention. We also performed western blot analysis of key proteins to probe the mechanisms of correlated signaling pathways.Results: We constructed "compound-target" (339 nodes and 695 edges) and "compound-disease" (414 nodes and 6458 edges) networks using interaction data. Topology analysis and molecular docking were used as secondary screens to identify key hubs of the network. Finally, the key component APS and biomarkers PIK3CG, AKT, and BCL2 were identified. The in vitro experimental results confirmed that APS can effectively inhibit TNBC cell activity, reduce invasion, promote apoptosis, and then counteract TNBC symptoms in a dose-dependent manner, most likely by inhibiting the PIK3CG/AKT/BCL2 pathway.Conclusion: This study provides a rational approach to discovering compounds with a polypharmacology-based therapeutic value. Our data established that APS intervenes with TNBC cell invasion, proliferation, and apoptosis via the PIK3CG/AKT/BCL2 pathway and could thus offer a promising therapeutic strategy for TNBC.

The Natural Products And Extracts: Anti-Triple-Negative Breast Cancer In Vitro

The Potential of Natural Products in the Treatment of Triple-negative Breast Cancer

The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers

Molecular mechanism of oroxyli semen against triple-negative breast cancer verified by bioinformatics and in vitro experiments

Epigenetics of Triple-Negative Breast Cancer via Natural Compounds

Progress in Triple Negative Breast Carcinoma Pathophysiology: Potential Therapeutic Targets.

Current Landscape of Personalized Clinical Treatments for Triple-Negative Breast Cancer.

Nanomaterial Technology and Triple Negative Breast Cancer

Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets

The treatment landscape of triple-negative breast cancer

Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer

The Latest Progress in Research on Triple Negative Breast Cancer (TNBC): Risk Factors, Possible Therapeutic Targets and Prognostic Markers.

Natural products and derivatives for breast cancer treatment: From drug discovery to molecular mechanism

High-throughput screening of ancient forest plant extracts shows cytotoxicity towards triple-negative breast cancer

Triple-negative breast cancer molecular subtyping and treatment progress

A Review of Natural Therapies Potentially Relevant in Triple Negative Breast Cancer Aimed at Targeting Cancer Cell Vulnerabilities

Recent treatment progress of triple negative breast cancer

Exploring the Potential of Nanomolecular Therapeutic Therapy Options, and Novel Biomarkers in Triple-negative Breast Cancer Treatment

Approach to the Triple Negative Breast Cancer in New Drugs Area

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method